public offering Archives | Page 2 of 2 | Be Korea-savvy
RedHill Biopharma Announces Closing of Concurrent Public Offering and Registered Direct Offering of its American Depositary Shares and Warrants and Partial Exercise of the Option of Underwriters

RedHill Biopharma Announces Closing of Concurrent Public Offering and Registered Direct Offering of its American Depositary Shares and Warrants and Partial Exercise of the Option of Underwriters

TEL-AVIV, Israel, Dec. 27 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced the closing of its previously announced underwritten public offering and its concurrent [...]

RedHill Biopharma Announces Proposed Concurrent Public Offering and Registered Direct Offering of its American Depositary Shares and Warrants

RedHill Biopharma Announces Proposed Concurrent Public Offering and Registered Direct Offering of its American Depositary Shares and Warrants

TEL-AVIV, Israel, Dec. 20 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that it intends to offer its American Depositary Shares (“ADSs”), each representing [...]

RedHill Biopharma Announces Withdrawal of Public Offering of its American Depositary Shares

RedHill Biopharma Announces Withdrawal of Public Offering of its American Depositary Shares

TEL-AVIV, Israel, Nov. 2 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that it has withdrawn the proposed underwritten public offering of its American [...]

RedHill Biopharma to Host Investor Conference Call Today at 18:00 EDT Following Announcement of Proposed Public Offering of its American Depository Shares

RedHill Biopharma to Host Investor Conference Call Today at 18:00 EDT Following Announcement of Proposed Public Offering of its American Depository Shares

TEL-AVIV, Israel, Nov. 1 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that it will host an investor conference call today, Tuesday November 1st, [...]

RedHill Biopharma Announces Proposed Public Offering of its American Depository Shares

RedHill Biopharma Announces Proposed Public Offering of its American Depository Shares

TEL-AVIV, Israel, Nov. 1 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that it intends to offer its American Depository Shares (“ADSs”), each representing [...]